Jane Street Group LLC boosted its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 137.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 28,729 shares of the medical instruments supplier's stock after buying an additional 16,635 shares during the period. Jane Street Group LLC owned 0.12% of ICU Medical worth $5,235,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its position in shares of ICU Medical by 9.3% during the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier's stock valued at $165,384,000 after purchasing an additional 77,506 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of ICU Medical by 18.3% during the third quarter. Quantinno Capital Management LP now owns 46,337 shares of the medical instruments supplier's stock valued at $8,444,000 after purchasing an additional 7,174 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of ICU Medical during the third quarter valued at about $3,116,000. Point72 Hong Kong Ltd purchased a new position in shares of ICU Medical during the third quarter valued at about $72,000. Finally, Captrust Financial Advisors grew its position in shares of ICU Medical by 54.2% during the third quarter. Captrust Financial Advisors now owns 2,969 shares of the medical instruments supplier's stock valued at $541,000 after purchasing an additional 1,043 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a report on Wednesday, November 13th. Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective for the company in a research note on Wednesday, December 11th. KeyCorp raised their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 13th. Raymond James raised their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research note on Thursday, September 12th. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $199.67.
Read Our Latest Report on ICUI
ICU Medical Trading Down 1.2 %
Shares of ICU Medical stock traded down $1.89 on Tuesday, hitting $157.17. 161,141 shares of the company traded hands, compared to its average volume of 270,068. The stock's 50 day moving average price is $170.34 and its 200-day moving average price is $152.40. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 52 week low of $86.80 and a 52 week high of $196.26. The company has a market cap of $3.85 billion, a PE ratio of -34.39 and a beta of 0.62.
Insider Activity
In related news, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total transaction of $153,682.92. Following the transaction, the director now directly owns 5,037 shares of the company's stock, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,364 shares of company stock valued at $6,869,878. Corporate insiders own 6.70% of the company's stock.
About ICU Medical
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.